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Abstract
Background: A number of approaches have been used to grade levels of evidence and the
strength of recommendations. The use of many different approaches detracts from one of the main
reasons for having explicit approaches: to concisely characterise and communicate this information
so that it can easily be understood and thereby help people make well-informed decisions. Our
objective was to critically appraise six prominent systems for grading levels of evidence and the
strength of recommendations as a basis for agreeing on characteristics of a common, sensible
approach to grading levels of evidence and the strength of recommendations.
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Methods: Six prominent systems for grading levels of evidence and strength of recommendations
were selected and someone familiar with each system prepared a description of each of these.
Twelve assessors independently evaluated each system based on twelve criteria to assess the
sensibility of the different approaches. Systems used by 51 organisations were compared with these
six approaches.
Results: There was poor agreement about the sensibility of the six systems. Only one of the
systems was suitable for all four types of questions we considered (effectiveness, harm, diagnosis
and prognosis). None of the systems was considered usable for all of the target groups we
considered (professionals, patients and policy makers). The raters found low reproducibility of
judgements made using all six systems. Systems used by 51 organisations that sponsor clinical
practice guidelines included a number of minor variations of the six systems that we critically
appraised.
Conclusions: All of the currently used approaches to grading levels of evidence and the strength
of recommendations have important shortcomings.
Background
In 1979 the Canadian task Force on the Periodic Health
Examination published one of the first efforts to explicitly
characterise the level of evidence underlying healthcare
recommendations and the strength of recommendations
[1]. Since then a number of alternative approaches has
been proposed and used to classify clinical practice guide-
lines [2-28].
The original approach used by the Canadian Task Force
was based on study design alone, with randomised con-
trolled trials (RCTs) being classified as good (level I) evi-
dence, cohort and case control studies being classified as
fair (level II) evidence and expert opinion being classified
as poor (level III) evidence. The strength of recommenda-
tion was based on the level of evidence with direct corre-
spondence between the two; e.g. a strong
recommendation (A) corresponded to there being good
evidence. A strength of the original Canadian Task Force
approach was that it was simple; the main weakness was
that it was too simple. Because of its simplicity, it was easy
to understand, apply and present. However, because it
was so simple there were many implicit judgements,
including judgements about the quality of RCTs, conflict-
ing results of RCTs, and convincing results from non-
experimental studies.
For example:
• Should a small, poorly designed RCT be considered level
I evidence?
• Should RCTs with conflicting results still be considered
level I evidence?
• Should observational studies always be considered level
II evidence, regardless of how convincing they are?
The original approach by the Canadian Task Force also
did not include explicit judgements about the strength of
recommendations, such as how trade-offs between the
expected benefits, harms and costs were weighed and
taken account of in going from an assessment of how
good the evidence is to determining the implications of
the results for practice.
The GRADE Working Group is an informal collaboration
of people with an interest in addressing shortcomings
such as these in systems for grading evidence and recom-
mendations. We describe here a critical appraisal of six
prominent systems and the results of the critical appraisal.
Methods
We selected systems for grading the level of evidence and
the strength of recommendations that we considered
prominent and that included features not captured by
other prominent systems. These were selected based on
the experience and knowledge of the authors through
informal discussion. A description of the most recent ver-
sion (as of summer 2000) of each of these systems
(Appendix 1 to 6), was prepared by one of the authors
familiar with the system, and used in this exercise. The fol-
lowing six systems were appraised: the American College
of Chest Physicians (ACCP, [see Additional file 1]) [21],
Australian National Health and Medical Research Council
(ANHMRC, [see Additional file 2]) [17], Oxford Centre
for Evidence-Based Medicine (OCEBM, [see Additional
file 3]) [16], Scottish Intercollegiate Guidelines Network
(SIGN, [see Additional file 4]) [18], US Preventive Services
Task Force (USPSTF, [see Additional file 5]) [22], US Task
Force on Community Preventive Services (USTFCPS, [see
Additional file 6]) [25].
These descriptions of the systems were given to the twelve
people who independently appraised the six systems, allBMC Health Services Research 2004, 4:38 http://www.biomedcentral.com/1472-6963/4/38
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of the authors minus GEV appraised the six systems, three
of the authors (DH, SH and DO'C) appraised as a group
and reported as one (see contributions). The 12 assessors
all had experience with at least one system and most had
helped to develop one of the six included systems. Twelve
criteria described by Feinstein [29] provided the basis for
assessing the sensibility of the six systems.
Criteria used to assess the sensibility of systems for grading 
evidence and recommendations
1. To what extent is the approach applicable to different
types of questions? -effectiveness, harm, diagnosis and
prognosis (No, Not sure, Yes)
2. To what extent can the system be used with different
audiences? -patients, professionals and policy makers
(Little extent, Some extent, Large extent)
3. How clear and simple is the system? (Not very clear,
Somewhat clear, Very clear)
4. How often will information not usually available be
necessary? (Often, Sometimes, Seldom)
5. To what extent are subjective decisions needed? (Often,
Sometimes, Seldom)
6. Are dimensions included that are not within the con-
struct (level of evidence or strength of recommendation)?
(Yes, Partially, No)
7. Are there important dimensions that should have been
included and are not? (No, Partially, Yes)
8. Is the way in which the included dimensions are aggre-
gated clear and simple? (No, Partially, Yes)
9. Is the way in which the included dimensions are aggre-
gated appropriate? (No. Partially, Yes)
10. Are the categories sufficient to discriminate between
different levels of evidence and strengths of recommenda-
tions? (No, Partially, Yes)
11. How likely is the system to be successful in discrimi-
nating between high and low levels of evidence or strong
and weak recommendations? (Not very likely, Somewhat
likely, Highly likely)
12. Are assessments reproducible? (Probably not, Not
sure, Probably)
No training was provided and we did not discuss the 12
criteria prior to applying them to the six systems.
Our independent appraisal of the six systems were sum-
marised and discussed. The discussion focused on differ-
ences in the interpretation of the criteria, disagreement
about the judgements that we made and sources of these
disagreements, the strengths and weaknesses of the six sys-
tems, and inferences based on the appraisals and subse-
quent discussion.
In order to identify important systems that we might have
overlooked following our appraisal of these six systems
we also searched the US Agency for Health Care Research
and Quality (AHRQ) National Guidelines Clearing House
for organisations that have graded two or more guidelines
in the Clearing House using an explicit system [30]. These
systems were compared with the six systems that we criti-
cally appraised.
Results
There was poor agreement among the 12 assessors who
independently assessed the six systems. A summary of the
assessments of the sensibility of the six approaches to rat-
ing levels of evidence and strength of recommendation is
shown in Table 1.
Discussion
The poor agreement among the assessors likely reflects
several factors. Some of us had practical experience using
one of the systems or used additional background infor-
mation related to one or more grading systems, and we
may have been biased in favour of the system with which
we were most familiar. Each criterion was applied to grad-
ing both evidence and recommendations. Some systems
were better for one of these constructs than the other and
we may have handled these discrepancies differently. In
addition each criterion may have been assessed relative to
different judgements about the evidence, such as an
assessment of the overall quality of evidence for an impor-
tant outcome (across studies) versus the quality of an
individual study. Some of the criteria were not clear and
were interpreted or applied inconsistently. For example, a
system might be clear and not simple or visa versa. We
likely differed in how stringently we applied the criteria.
Finally, there was true disagreement.
There was agreement that the OCEBM system works well
for all four types of questions. There was disagreement
about the extent to which the other systems work well for
questions other than effectiveness. It was noted that some
systems are not intended to address other types of ques-
tions and it is not clear that it is important that a system
should address all four types of questions that we consid-
ered (effectiveness, harm, diagnosis, prognosis), although
criteria for assessing individual studies must take this into
account [31,32].BMC Health Services Research 2004, 4:38 http://www.biomedcentral.com/1472-6963/4/38
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Most of us did not find that any of the systems are likely
to be suitable for use by patients. Almost all agreed that
the ACCP system was suitable for professionals and most
considered that the USPSTF system was suitable for pro-
fessionals. There was not much agreement about the suit-
ability of any of the other systems for professionals or
about the suitability of any of the systems for policy mak-
ers, although most assessed the USTFCPS system to be
suitable for policy makers.
There was no agreement that any of the systems are clear
and simple, although USPSTF, ACCP and SIGN systems
were generally assessed more favourably in this regard. It
was generally agreed that the clearer a system was the less
simple it was; e.g. the OCEBM system is clear but not sim-
ple for categorising the level of evidence. There was some
confusion regarding whether we were assessing how clear
and simple the system was to guideline developers (as
some interpreted this criterion) or how clear and simple
the outcome of applying the system was to guideline users
(as others interpreted this criterion). Either way, the sim-
pler a system is the less clear it is likely to be.
Most of us judged that for most of the systems necessary
information would not be available at least sometimes.
The OCEBM system came out somewhat better than the
other systems and lack of availability of necessary infor-
mation was considered to be less of a problem for the
USTFCPS system. However, the OCEBM and USTFCPS
systems were considered by most to be missing dimen-
sions which may, in part, explain why missing informa-
tion was considered to be less of a problem. This would be
the case to the extent the missing dimensions were the
ones for which information would often or sometimes
not be available. The dimension for which we considered
that information would most often be missing was trade-
offs; i.e. knowledge of the preferences or utility values of
those affected. Additional problems were identified in
relationship to complex interventions and counselling,
particularly with the USTFCPS and USPSTF systems. It was
pointed out that the USTFCPS system addressed this prob-
lem by including availability of information about the
intervention as part of its assessment of the quality of
evidence.
Table 1: Summary of assessments of the sensibility of six approaches to rating levels of evidence and strength of recommendation
Criteria1 ACCP ANHMRC2 USTFCPS OCEBM SIGN USPSTF3
No Yes No Yes No Yes No Yes No Yes No Yes
1. Applicable to different questions:
Effectiveness 12 2 8 1 11 12 1 11 2 9
H a r m 11 1 5 5 1 7 4 11 1 1 3 8 2 2 7
D i a g n o s i s 732 4 4 2 9 3 1 2 525 2 2 7
P r o g n o s i s 6 3 32 5 39 2 1 1 1 4 3 53 3 5
2. Can be used by:
Professionals 1 11 1 5 3 7 4 1 6 5 5 7 3 8
Policy makers 1 5 6 1 5 3 1 2 9 3 7 2 2 6 4 1 4 6
P a t i e n t s 453 5 5 6 3 3 93 75 4 6 1
3 .  C l e a r  a n d  s i m p l e 1 5 62 6 12 8 22 4 51 5 61 4 7
4. Information not available 8 4 1 5 3 1 6 5 4 8 1 7 4 1 9 2
5. Subjective decisions 2 1
0
522 552 7 5 5 7 29
6. Inappropriate dimensions 1 3 8 1 6 2 4 6 1 10 1 2 8 1 4 6
7. Missing dimensions 1 6 5 2 2 4 5 4 3 9 3 1 5 4 3 2 5 4
Aggregation of dimensions:
8. Clear and simple 1 5 6 4 1 2 2 2 7 3 4 4 6 6 2 7 2
9 .  A p p r o p r i a t e 6 53 1 13 4 42 5 41 4 61 5 5
10. Sufficient categories 1 4 6 4 2 1 5 7 2 2 7 1 2 9 1 10
11. Likely to discriminate 7 5 2 5 1 1 9 2 2 4 6 5 7 4 7
12. Assessments reproducible 1 8 3 4 4 2 7 2 7 4 1 8 2 1
0
1See Criteria described in Methods.
2Two people did not assess the ANHMRC because it was more descriptive and others responded not applicable for some questions.
3One person did not assess the USPST and one person had two responses on questions 3 and 4.BMC Health Services Research 2004, 4:38 http://www.biomedcentral.com/1472-6963/4/38
Page 5 of 7
(page number not for citation purposes)
Most of the systems were assessed to require subjective
decisions at least to some extent. The OCEBM system
again stood out as being assessed more favourably,
although it may be related to omission of dimensions that
require more subjective decisions. Judgement is clearly
needed with any system. The aim should be to make
judgements transparent and to try to protect against bias
in the judgements that are made by being systematic and
explicit.
Inclusion of dimensions that are not within the constructs
being graded was not considered a problem for most of
the systems by most of us. Several people considered that
it might be a problem for the USTFCPS and USPSTF sys-
tems. On the other hand, all of the systems were evaluated
to be missing at least one important dimension by at least
one person. The challenge of missing dimensions were
considered less of a problem for the ACCP and ANHMRC
systems. There was not agreement about any of the sys-
tems having a clear and simple approach to aggregating
the dimensions, although this was considered to be less of
a problem for the ACCP, SIGN and USTFCPS systems.
There was also not agreement on the appropriateness of
how the dimensions were aggregated. This was considered
to be more of a problem for the ANHMRC and USTFCPS
systems than the other four systems, all of which were
considered to have taken an approach to aggregating the
dimensions that was at least partially inappropriate by
more than half of us.
Most of us considered that most of the systems had suffi-
cient categories, with the exception of the ANHMRC sys-
tem. There was almost agreement that the USPSTF system
has sufficient categories. We agreed that it is possible to
have too many categories as well as too few, the OCEBM
system being an example of having too many categories.
There was not agreement that any of the systems are likely
to discriminate successfully, although everyone thought
that the ACCP, SIGN and USPSTF systems are somewhat
to highly likely to discriminate. Lastly, we largely agreed
that we were not sure how reproducible assessments are
using any of the systems, although half of us considered
that assessments using the ANHMRC system are unlikely
to be reproducible and about 1/3 considered that assess-
ments using the OCEBM and ACCP systems are likely to
be reproducible.
We identified 22 additional organisations that have pro-
duced 10 or more practice guidelines using an explicit
approach to grade the level of evidence or strength of rec-
ommendations. Another 29 have produced between two
and nine guidelines using an explicit approach. These sys-
tems include a number of minor variations of the six sys-
tems that we appraised in detail.
There was generally poor agreement between the individ-
ual assessors about the scoring of the six approaches using
the 12 criteria. However, there was general agreement that
none of these six prominent approaches to grading the
levels of evidence and strength of recommendations ade-
quately addressed all of the important concepts and
dimensions that we thought should be considered.
Although we limited our appraisal to six systems all of the
additional approaches to grading levels of evidence and
strength of recommendations that we identified were, in
essence, variations of the six approaches that we had crit-
ically appraised. Therefore we are confident that we did
not miss any important grading systems available at the
time when these assessments were undertaken.
Based on discussions following the critical appraisal of
these six approaches, we agreed on some conclusions:
• Separate assessments should be presented for judge-
ments about the quality of the evidence and judgements
about the balance of benefits and harms.
• Evidence for harms should be assessed in the same way
as evidence for benefits, although different evidence may
be considered relevant for harms than for benefits; e.g.
local evidence of complication rates may be considered
more relevant than evidence of complication rates from
trials for endarterectomy.
• Judgements about the quality of evidence should be
based on a systematic review of the relevant research.
• Systematic reviews should not be included in a hierarchy
of evidence (i.e. as a level or category of evidence). The
availability of a well-done systematic review does not cor-
respond to high quality evidence, since a well-done review
might include anything from no studies to poor quality
studies with inconsistent results to high quality studies
with consistent results.
• Baseline risk should be taken into consideration in
defining the population to whom a recommendation
applies. Baseline risk should also be used transparently in
making judgements about the balance of benefits and
harms. When a recommendation varies in relationship to
baseline risk, the evidence for determining baseline risk
should be assessed appropriately and explicitly.
• Recommendations should not vary in relationship to
baseline risk if there is not adequate evidence to guide reli-
able determinations of baseline risk.BMC Health Services Research 2004, 4:38 http://www.biomedcentral.com/1472-6963/4/38
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Conclusions
Based on discussions of the strengths and limitations of
current approaches to grading levels of evidence and the
strength of recommendations, we agreed to develop an
approach that addresses the major limitations that we
identified. The approach that the GRADE Working Group
has developed is based on the discussions following the
critical appraisal reported here and a pilot study of the
GRADE approach [33]. Based on the pilot testing and the
discussions following the pilot, the GRADE Working
Group has further developed the GRADE system to its
present format [34].
The GRADE Working Group has continued to grow as an
informal collaboration that meets one or two times per
year. The group maintains web pages http://www.grade
workinggroup.org and a discussion list.
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